Company news
Enzolytics Inc. news in 2023
Enzolytics Inc.'s news releases, calls and decks from 2023, newest first.
Enzolytics, Inc. Files Amended December 31, 2022 OTC Report with Audited Financials and Unaudited September 30, 2023 Quarterly Disclosure
November 19, 2023
Enzolytics Announces the Signing of the Business Combination Agreement with Sagaliam Acquisition Corp (SAGA)
September 17, 2023
Sagaliam acquisition corp. announces execution of definitive business combination agreement and receipt of NASDAQ listing delinquency letter
September 14, 2023
Patient Population for the Clinical Trials of ITV-1 has been Established by the European Medicines Agency ("EMA")
September 5, 2023
Biogenysis, Inc. Announces Partnering with Khalpey AI Lab and Contenta, Ltd. to Incorporate AI in Microbiome Analysis to Identify Biomarkers for Use in Accurately Predicting Alzheimer's Disease Onset and Prevention.
September 4, 2023
Biogenysis’ International Patent Application, Covering Its Anti-SARS-CoV-2 Monoclonal Antibodies, Advances to Prosecution in Europe and as a U.S. National Stage Application.
August 23, 2023
Virogentics, Inc. Receives Permit for Export to Africa of the ITV-1 Immunotherapy Solidifying the Scheduled Administration of the Treatment
August 7, 2023
Virogentics, Inc. Provides Update on African Project, European Medicine Agency Application and Clinical Trials for Application for Type 2 Diabetes
August 3, 2023
CORRECTION FROM SOURCE: Virogentics Announces Approval of Final Protocol from the Dept for HIV and AIDS, Ministry of Health of the DRC
July 23, 2023
Virogentics, Inc to Introduce a Dietary Supplement Offers Additional Information on ITV-1 and Diabetic Clinical Trials
July 23, 2023
Biogenysis Inc. Announces a Collaboration with Khalpey AI Lab in using Artificial Intelligence (AI) for Unveiling Potential Biomarkers and Predicting the Onset or Prevention of Alzheimer's Disease.
July 20, 2023
Enzolytics Inc. Files Supplemental Information Report on the Sale of Biogenysis, Inc. and Virogentics, Inc to Sagaliam Acquisition Corp.
July 10, 2023
Virogentics, Inc to Introduce a Dietary Supplement Offers Additional Information on ITV-1 And Diabetic Clinical Trials
July 5, 2023
Enzolytics, Inc. Reports Amendment to Non-Binding Term Sheet with the Special Purpose Acquisition Company Sagaliam Acquisition Corp.
June 28, 2023
Enzolytics Offers Update on Virogentics, Inc ITV-1 African Project
June 25, 2023
Enzolytics Offers Update on Virogentics and Sale Transaction, Clinical Trials Progress on European Medicine Agency (EMA) Permitting and Arican ITV-1 Project
June 4, 2023
Virogentics and Enzolytics Refute Misleading Information Being Circulated on Social Media and Other Internet Outlets Biogenesis to be Featured in June Issue of Life Science Review
May 18, 2023
Virogentics Inc. Receives Report from Bulgarian Academy of Sciences Administration of ITV-1 to Begin First Week in June 2023
May 15, 2023
Virogentics Inc. Announces Pilot Clinical Trial of ITV-1 at National Center for Endocrinology in Bulgaria and Expansion of Nutraceutical Line
May 7, 2023
Enzolytics Inc. Continues Progress with Business Combination; Biogenysis Announces Team and Plans for Success
April 26, 2023
Enzolytics, Inc. Finalizing Regulatory Labeling Requirements for Delivery of ITV-1 Treatments for Use in Hospitals in Central and Eastern Africa - Company also Provides Additional Details on the Sale of Biogenysis and Virogentics
April 20, 2023
Enzolytics, Inc. Announces Execution of Non-Binding Term Sheet with the Special Purpose Acquisition Company Sagaliam Acquisition Corp. and Updates the Progress on the African Project
April 16, 2023
Enzolytics Announces Progress in the Development and Patenting of Feline Leukemia Monoclonal Antibodies
April 3, 2023
Enzolytics, Inc. Highlights Plans for Promotion of IPF Immune(TM), Its Patented Nutraceutical Supplement
February 27, 2023
Enzolytics Announces Preliminary Results of GLP Toxicology Study for its anti-HIV Therapeutic ITV-1 and Production of ITV-1 for Initiation of Registration in Africa
February 7, 2023
Enzolytics to Develop Feline Monoclonal Antibodies
January 2, 2023